GENGOS ANDREW (Chief Financial Officer) purchased 66.7% of their position (10K shares) of TERNS PHARMACEUTICALS, INC. on the open market
Open‑market purchase worth $39.3K — a major conviction buy. The strongest form of insider conviction signal.
P · 2 purchases
Filed: 6/30/2025ACC: 0001562180-25-005120
Officer· Chief Financial Officer
Since Feb 2025
+10K
Net shares
Net buyer
$39.3K
Total acquired
2
Open market trades
2B · 0S
2
Total transactions
10K acquired
Non-Derivative Transactions2
Common Stock
Direct
Shares
+5K
Price / share
$3.93
Trade value
$19.63K
% of position
33.3%
6/27/2025
15K→20K
Common Stock
Direct
Shares
+5K
Price / share
$3.93
Trade value
$19.65K
% of position
25.0%
6/27/2025
20K→25K
Total
Net shares
+10K
Net value
$39.28K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/27/2025 | P · Purchase | +5K | $3.93 | $19.63K | 33.3% | 15K | 20K |
| Common Stock Direct | 6/27/2025 | P · Purchase | +5K | $3.93 | $19.65K | 25.0% | 20K | 25K |
| Total | +10K | $39.28K | ||||||
Derivative Transactions0
No derivative transactions reported